Conference Details - Agenda
Continuing Education Information
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.
Seventh International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
Jumeirah Essex House
New York, NY
March 26-27, 2010
Friday, Mar 26, 2010
| 7:30 am | Registration and Continental Breakfast |
| 8:00 am | Welcome, Introductions, and Presession Survey J. Tate Thigpen |
| Friday Debates: Part 1 Moderator: Marcus Randall |
|
| Debate 1: Combined modality therapy that includes radiation is the treatment of choice for locally advanced (stage III-IVA) endometrial carcinoma. |
|
| 8:15 am | PRO Marcus Randall |
| 8:30 am | CON Daniela Matei |
| 8:45 am | Clinical Relevance Marcus Randall |
| 8:50 am | Panel Discussion Daniela Matei Marcus Randall |
| Debate 2: Concurrent platinum-based chemotherapy plus radiation therapy is the treatment of choice for stage IIB-IVA carcinoma of the cervix. |
|
| 9:05 am | PRO Krishnansu S. Tewari |
| 9:20 am | CON Gillian Thomas |
| 9:35 am | Clinical Relevance Marcus Randall |
| 9:40 am | Panel Discussion Krishnansu S. Tewari Gillian Thomas |
| 9:55 am | Break |
| Antiangiogenic Agents in Gynecologic Malignancies Moderator: Michael J. Birrer |
|
| 10:10 am | Why Target Angiogenesis? Robert A. Burger |
| 10:35 am | Which Agents? Robert L. Coleman |
| 11:00 am | What Schedule? Agustin Garcia |
| 11:30 am | Panel Discussion Robert A. Burger Robert L. Coleman Agustin Garcia |
| Working Lunch: Uterine Cancer Case Presentations and Discussion Moderator: Marcus Randall |
|
| 11:50 am | Break to Get Lunch |
| 12:20 pm | Clinical Scenario Presentations and Panel Discussion Robert A. Burger Robert L. Coleman Agustin Garcia Gillian Thomas |
| 1:20 pm | Break |
| Friday Debates: Part 2 Moderator: Marcus Randall |
|
| Debate 3: All patients with serous and clear cell carcinomas of the endometrium should receive chemotherapy as part of their treatment. |
|
| 1:35 pm | PRO David Scott Miller |
| 1:50 pm | CON Eric L. Eisenhauer |
| 2:05 pm | Clinical Relevance Marcus Randall |
| 2:10 pm | Panel Discussion Eric L. Eisenhauer David Scott Miller |
| Debate 4 (in 3 parts): The chemotherapy of choice for the treatment of uterine carcinosarcoma is: |
|
| 2:25 pm | Paclitaxel Plus a Platinum Compound Matthew Powell |
| 2:35 pm | Ifosfamide Plus a Taxane J. Tate Thigpen |
| 2:45 pm | An Antimetabolite Plus a Taxane D. Scott McMeekin |
| 2:55 pm | Clinical Relevance Marcus Randall |
| 3:00 pm | Postsession Survey and Panel Discussion Matthew Powell J. Tate Thigpen |
| 3:15 pm | Adjourn |
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology
- Lilly USA, LLC
- Eisai, Inc.
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
- sanofi-aventis U.S.